XOMA Royalty (XOMA) Amortizatization of Intangibles (2012 - 2026)
XOMA Royalty's (XOMA) quarterly Amortizatization of Intangibles came in at $892000.0 in Q1 2026, up 63.97% year-on-year from $544000.0 in Q1 2025, and up 0.9% quarter-over-quarter from $884000.0 in Q4 2025.
XOMA Royalty (XOMA) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
XOMA Royalty has disclosed Amortizatization of Intangibles across 5 years of filings, most recently posting $892000.0 for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $892000.0, up 63.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 172.12% YoY), and the FY2025 annual result was $3.0 million, up 1337.38% from the prior year.
- Amortizatization of Intangibles came in at $892000.0 for Q1 2026 at XOMA Royalty, up from $884000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $892000.0 in Q1 2026 to a low of $224000.0 in Q2 2023.
- The 3-year median for Amortizatization of Intangibles is $544000.0 (2025), against an average of $527777.8.
- Peak annual rise in Amortizatization of Intangibles reached 63.97% in 2026, while the deepest fall reached 63.97% in 2026.
- XOMA Royalty's Amortizatization of Intangibles stood at $224000.0 in 2023, then surged by 294.64% to $884000.0 in 2025, then increased by 0.9% to $892000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $892000.0 (Q1 2026), $884000.0 (Q4 2025), and $878000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - | 892,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 892,000.00 |
| Mar 31, 2026 | 892,000.00 |
| Dec 31, 2025 | 884,000.00 |
| Dec 31, 2025 | 884,000.00 |
| Sep 30, 2025 | 878,000.00 |
| Sep 30, 2025 | 878,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Jun 30, 2025 | 655,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | 224,000.00 |
| Sep 30, 2023 | 224,000.00 |
| Jun 30, 2023 | 224,000.00 |
| Jun 30, 2023 | 224,000.00 |
| Mar 31, 2023 | 225,000.00 |
| Mar 31, 2023 | 225,000.00 |
| Sep 30, 2013 | 400,000.00 |
| Sep 30, 2013 | 400,000.00 |